Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
about
Oncogenic kinase fusions: an evolving arena with innovative clinical opportunitiesHepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genesRole of cancer-associated fibroblasts in invasion and metastasis of gastric cancerJAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indicationsMolecular classification of gastric cancer: Towards a pathway-driven targeted therapyThe potential of molecular markers to improve interventions through the natural history of oesophageal squamous cell carcinomaIdentifying and targeting tumor-initiating cells in the treatment of breast cancerLB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potentialSTAT3: A Novel Molecular Mediator of Resistance to ChemoradiotherapyPersonalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?Developmental therapeutics for inflammatory breast cancer: Biology and translational directionsThe role of STAT3 in autophagyNovel multiplexed assay for identifying SH2 domain antagonists of STAT family proteinsThe natural chemopreventive agent sulforaphane inhibits STAT5 activityThe cell survival pathways of the primordial RNA-DNA complex remain conserved in the extant genomes and may function as proto-oncogenesIntegration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci.PIAS3 expression in squamous cell lung cancer is low and predicts overall survival.Ruxolitinib: A Review in Polycythaemia Vera.Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignanciesInhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burdenTherapeutic modulators of STAT signalling for human diseasesGaliellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cellsDownregulation of UHRF1 increases tumor malignancy by activating the CXCR4/AKT-JNK/IL-6/Snail signaling axis in hepatocellular carcinoma cells.A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status.The synthetic α-bromo-2',3,4,4'-tetramethoxychalcone (α-Br-TMC) inhibits the JAK/STAT signaling pathway.Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesTargeting an IKBKE cytokine network impairs triple-negative breast cancer growth.STAT3 and STAT5b polymorphism contributes to breast cancer risk and clinical outcomes.Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.Development and validation of a novel platform-independent metastasis signature in human breast cancer.An epigenetic memory of pregnancy in the mouse mammary glandIdentification of mRNA isoform switching in breast cancer.A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)The Chemopreventive Phytochemical Moringin Isolated from Moringa oleifera Seeds Inhibits JAK/STAT Signaling.Identification of a Dual Inhibitor of Janus Kinase 2 (JAK2) and p70 Ribosomal S6 Kinase1 (S6K1) Pathways.Lentiginoses in polycythemia vera patient: Is there a role for JAK2 (V617F) mutation?Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies.
P2860
Q26768158-9411A9E2-40DD-4DC4-B263-074EAD1329B8Q26772317-51DD68C7-02D5-4773-AC4C-0E1B695B3EC9Q26781520-399B309B-8BA9-44FF-BC33-33FB203720B5Q26782539-AA8245EA-2C9F-40B3-B7DC-801498D5A639Q26798420-63011930-FEBA-49DB-88E5-250B8DBBC423Q26829483-F8BF90F6-F474-4262-A2EF-851344E8499DQ26851827-0C72E0FC-71BA-45D7-83AA-B98B809F11B2Q26865711-A9230FE8-99BC-47D0-9904-2B1E4D69B886Q27003190-D616358C-ACBB-4698-A600-10D929693582Q28066268-C25A6C36-CA8A-465B-B8E2-7C8715C925A1Q28075322-9B428D76-90B8-43BA-97D8-FEE4BC6C5804Q28084959-EC29D815-245D-46F8-9ACE-F7BEADE2CC91Q28535402-9E77AAE7-C825-49F3-A27C-2E57EFE25C87Q28539573-AAE37211-1812-408E-BCD4-8394F7E6C0A7Q28649653-209476C3-3EE8-4E1A-A98B-CAC3357BA1EAQ30275132-058DA2C9-49C5-42FD-9F60-37B0F83051D6Q30405870-D60A20CF-FC2C-4A01-BDCA-2758C6CE79EAQ33425781-17186F5D-678F-4B37-8CFB-F1584AF97DCBQ33437478-18DCA69D-1C74-4456-BED2-384E7ECC1462Q33628532-E12B8A34-AC0D-4F78-AFAE-AE94DCB4D024Q33684732-5F48880F-0CE4-462A-AC77-0FF09A0A4A02Q33718420-BF21310E-0FA9-44B7-8296-9F05AB0A9977Q33765984-AB50BB4B-F321-4FAB-A6BC-5DE2FDC22F4EQ33897070-6D87AE8B-5042-421E-886E-4AD49D26A9E4Q34086875-728EF590-70EE-4278-BE2C-7D66F366C7CBQ34352295-55CF0777-6377-4338-9F01-D21860E59EDEQ35111380-EF731770-344F-4139-A5F4-1C4D8BA3A53BQ35132241-CE345D2E-9115-4043-85EF-6153D2751E3FQ35145319-6FDBE326-334A-4FD6-BEA2-CE32427E776DQ35405293-F3CAEC7F-5B95-408E-813A-9196CD3A9847Q35565555-F771CEF3-3261-4C8B-818F-32E9653FAB9BQ35606889-5FAD6BEB-4A9C-483B-AE85-9459751AD3BAQ35629773-678E963C-4FCC-4C91-8CA0-0121996DE134Q35945158-79345F7B-4413-40EC-83B0-C5B5E69D3E6BQ35987564-D34A058B-EF59-47CD-9D2F-FD323DF9104CQ36053065-C0A5E0E7-74E2-4381-A5DB-5C687047FC0EQ36092925-D7E86A3B-6473-4011-BC13-4508FF81EDACQ36093112-54204060-A1EA-4032-A890-5666119368C2Q36202610-DC9DCD54-BC52-4237-9BBE-FF6D7BA4AB23Q36298736-DA907923-5AB5-4B6D-BAAD-D2EAFC7A3B37
P2860
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
@en
type
label
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
@en
prefLabel
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
@en
P2860
P1476
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.
@en
P2093
Alfonso Quintás-Cardama
P2860
P304
P356
10.1158/1078-0432.CCR-12-0284
P407
P577
2013-02-13T00:00:00Z